A carregar...
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
Atherosclerotic cardiovascular disease remains a major cause of death and disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovascular event rates...
Na minha lista:
| Publicado no: | Circ Cardiovasc Qual Outcomes |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7665275/ https://ncbi.nlm.nih.gov/pubmed/31331194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCOUTCOMES.118.005404 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|